PMID- 37287751
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230610
IS  - 2296-889X (Print)
IS  - 2296-889X (Electronic)
IS  - 2296-889X (Linking)
VI  - 10
DP  - 2023
TI  - DPP-4 inhibitors for treating T2DM - hype or hope? an analysis based on the 
      current literature.
PG  - 1130625
LID - 10.3389/fmolb.2023.1130625 [doi]
LID - 1130625
AB  - DPP-4 inhibition is an interesting line of therapy for treating Type 2 Diabetes 
      Mellitus (T2DM) and is based on promoting the incretin effect. Here, the authors 
      have presented a brief appraisal of DPP-4 inhibitors, their modes of action, and 
      the clinical efficiency of currently available drugs based on DPP-4 inhibitors. 
      The safety profiles as well as future directions including their potential 
      application in improving COVID-19 patient outcomes have also been discussed in 
      detail. This review also highlights the existing queries and evidence gaps in 
      DPP-4 inhibitor research. Authors have concluded that the excitement surrounding 
      DPP-4 inhibitors is justified because in addition to controlling blood glucose 
      level, they are good at managing risk factors associated with diabetes.
CI  - Copyright (c) 2023 Saini, Sharma and Khan.
FAU - Saini, Kunika
AU  - Saini K
AD  - Molecular Modelling and Drug Design Laboratory, Department of Chemistry, 
      University of Delhi, New Delhi, India.
FAU - Sharma, Smriti
AU  - Sharma S
AD  - Molecular Modelling and Drug Design Laboratory, Department of Chemistry, 
      University of Delhi, New Delhi, India.
FAU - Khan, Yousuf
AU  - Khan Y
AD  - Molecular Modelling and Drug Design Laboratory, Department of Chemistry, 
      University of Delhi, New Delhi, India.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20230523
PL  - Switzerland
TA  - Front Mol Biosci
JT  - Frontiers in molecular biosciences
JID - 101653173
PMC - PMC10242023
OTO - NOTNLM
OT  - (GLP)-1
OT  - DPP-4 enzyme
OT  - DPP-4 inhibitors
OT  - T2DM
OT  - incretin effect
OT  - insulin
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2023/06/08 06:42
MHDA- 2023/06/08 06:43
PMCR- 2023/01/01
CRDT- 2023/06/08 04:23
PHST- 2022/12/28 00:00 [received]
PHST- 2023/05/08 00:00 [accepted]
PHST- 2023/06/08 06:43 [medline]
PHST- 2023/06/08 06:42 [pubmed]
PHST- 2023/06/08 04:23 [entrez]
PHST- 2023/01/01 00:00 [pmc-release]
AID - 1130625 [pii]
AID - 10.3389/fmolb.2023.1130625 [doi]
PST - epublish
SO  - Front Mol Biosci. 2023 May 23;10:1130625. doi: 10.3389/fmolb.2023.1130625. 
      eCollection 2023.